Nova Eye Medical Limited announced the results of a retrospective case series which demonstrating the efficacy and safety of canaloplasty using the Company's proprietary iTrackTM canaloplasty microcatheter over a 60-month follow-up period. The retrospective case series data. iTrackTM canaloplasty performed as a standalone procedure or in conjunction with cataract surgery was found to be an effective option for maintaining a sustained IOP reduction in patients with OAG up to 5 years from 19.8 ± 5.2 (n=27) at baseline to 15.0 ± 2.6 (n=26), 15.6 ± 3.3 (n=25), 14.7 ± 3.8 (n=21), 14.6 ± 3.0 (n=18) and 14.4 ± 3.3 (n=14) at 12, 24, 36, 48 and 60 months respectively. iTrackTM canaloplasty was also effective in reducing glaucoma medication dependence, with the mean number of medications falling from 1.93 at baseline to 1.21 at 60- months and 57% of eyes on 1 medication or less at 60-months.